BankPlus Trust Department Grows Position in Gilead Sciences, Inc. $GILD

BankPlus Trust Department boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 333.3% in the second quarter, Holdings Channel.com reports. The firm owned 650 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the quarter. BankPlus Trust Department’s holdings in Gilead Sciences were worth $72,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. One Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares during the period. Ariel Investments LLC grew its holdings in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after purchasing an additional 30,630 shares during the period. Golden State Wealth Management LLC grew its holdings in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 109 shares during the period. Covea Finance grew its holdings in shares of Gilead Sciences by 69.5% during the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after purchasing an additional 21,200 shares during the period. Finally, Swedbank AB boosted its holdings in Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock worth $237,393,000 after acquiring an additional 16,663 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on GILD shares. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday. Rothschild & Co Redburn upped their price target on Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, September 12th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Finally, Royal Bank Of Canada increased their target price on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $117.67.

Gilead Sciences Stock Performance

GILD stock opened at $118.25 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a market cap of $146.73 billion, a P/E ratio of 23.56, a P/E/G ratio of 0.79 and a beta of 0.34. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83. The stock’s 50 day simple moving average is $114.48 and its 200 day simple moving average is $110.12.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock valued at $9,402,130. Corporate insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.